TRANXENE (clorazepate dipotassium) is a benzodiazepine.
TRANXENE is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.
TRANXENE tablets are indicated as adjunctive therapy in the management of partial seizures.
The effectiveness of TRANXENE tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient.
TRANXENE tablets are indicated for the symptomatic relief of acute alcohol withdrawal.
Published Studies Related to Tranxene (Clorazepate)
Clorazepate dipotassium versus midazolam for premedication in clear corneal cataract surgery. [2003.10]
PURPOSE: To evaluate and compare the efficacy of oral clorazepate dipotassium (Tranxilium) and intravenous midazolam (Dormicum) as premedication agents in retrobulbar anesthesia and clear corneal phacoemulsification with intraocular lens (IOL) implantation. SETTING: Department of Ophthalmology, University of Essen, Essen, Germany... CONCLUSIONS: Anterograde amnesia occurred more frequently and patients expected less pain before surgery with midazolam. Both anesthetic agents provided safe and effective premedication for retrobulbar anesthesia in clear corneal cataract surgery.
Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. [1999.09]
The efficacy of trazodone and clorazepate to relieve anxiety and depressive symptoms in 21 HIV-positive subjects with adjustment disorders was determined in a 28-day single-centre, randomized, double-blind study. Subjects were evaluated using the Hospital Anxiety and Depression Scale, the Revised Symptom Checklist, the European Organization for Research and the Treatment of Cancer Quality of Life Questionnaire, and a binary criterion based on the Clinical Global Impression...
Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. 
The efficacy of trazodone (mean once-daily dose 111.5 +/- 36.3 mg) versus clorazepate (mean once-daily dose 17.5 +/- 7.5 mg) to relieve anxious and depressive symptoms in 18 patients undergoing treatment for breast cancer was investigated in a 28-day randomized, double-blind study...
Effects of clorazepate, diazepam, and oxazepam on a laboratory measurement of aggression in men. [1998.07]
The effects of three benzodiazepines on human aggressive behavior were examined in 44 medically healthy men. Volunteers were administered either placebo, 10 mg diazepam, 15 mg chlorazepate, or 50 mg oxazepam orally using double-blind procedures...
Preoperative anxiolysis with minimal sedation in elderly patients: bromazepam or clorazepate-dipotassium? [1998.01]
BACKGROUND: In elderly patients undergoing ophthalmic surgery the loss of co-operation due to over-sedation, induced by drugs given preoperatively, may jeopardise the success of microsurgery performed under regional anaesthesia. The aim of this study was to compare the psychotropic effects of bromazepam and clorazepate-dipotassium, two benzodiazepines with predominantly anxiolytic and only weak sedative action... CONCLUSION: Bromazepam is superior to clorazepate in its anxiolytic action and suitable as preoperative medication in the elderly patient because of lack of overt sedative effects.
Clinical Trials Related to Tranxene (Clorazepate)
Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression [Recruiting]
To evaluate the comparative efficacy and security of Continuation Electroconvulsive Therapy
associated with pharmacotherapy versus pharmacotherapy alone in the prevention of depressive
Demographic and clinical variables will be collected and side effects scales and
neurocognitive battery will be performed. Variables of efficacy: relapse percentage in both
groups in one year (primary variable); time without relapse. Main variable of security:
occurrence of side effects and neurocognitive performance.
DESIGN: Randomized controlled clinical trial.
104 outpatients diagnosed with unipolar depression (DSM-IV-R criteria) who had remitted with
a course of bilateral ECT. They will be randomized to two groups of treatment.
SETTING: Psychiatry Department at Bellvitge University Hospital.
ANALYSIS: Descriptive analysis of clinical variables; survive analysis and Cox model of
Reports of Suspected Tranxene (Clorazepate) Side Effects
Thrombotic Microangiopathy (6),
Cardio-Respiratory Arrest (6),
Intestinal Ischaemia (6),
Intestinal Obstruction (6),
Confusional State (5),
Condition Aggravated (5), more >>
Page last updated: 2006-01-31